HTB

Side effects

Vitamin based protocol for the treatment for lactic acidosis

Osteonecrosis in HIV

Indinavir nephrolithiasis more prevalent than initially thought

HIV protease inhibitors associated with hepatic cytolysis

Inflammatory stimulus may contribute to HIV lipodystrophy

Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)

Reports on lipodystrophy and metabolic complications

Adverse effects of antiretroviral therapy

Efavirenz side effects become long-term for over one in three

Lipodystrophy: the current state of play

Metabolic effects – bone density and avascular necrosis

Lipoatrophy and facial wasting

Lactic acidosis

Mitochondrial toxicity reports

Crystalluria common in HIV-positive patients using indinavir

HAART: enough to make your hair curl?

Metabolic and lipodystropy issues: confusion continues to reign

Switching studies: Can viral load be maintained and metabolic or fat redistribution significantly improved?

Mitochondrial DNA (mtDNA) damage in semen as surrogate marker for nucleoside analogue toxicity

Incidence of adverse events at 4 weeks correlates with adherence and virologic failure at 4 months

Prednisone and nevirapine rash

Study of amino acid methionine for treatment of myelopathy

3rd report of patient whose NRTI-associated lactic acidosis responded to riboflavin (vitamin B2)

Mitochondrial toxicities of nucleoside reverse transcriptase inhibitors

Exercise testing in HIV patients with random increased lactic acid levels: evidence for a reduced anaerobic threshold with a pattern of mitochondrial dysfunction

Accelerated bone mineral loss in HIV-positive patients receiving potent antiretroviral therapy

Irreversible renal dysfunction linked to long-term indinavir therapy

L-Acetyl Carnitine (LAC) improves symptoms of peripheral neuropathy (PN): evidence for increases in cutaneous innervation

Decreased bone mineral density and HIV protease inhibitors

Post navigation